Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Geron Corporation Stock Bolted Higher in the First Half of 2019

By George Budwell - Jul 8, 2019 at 11:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Geron's stock has rebounded nicely in the first half of 2019.

What happened

Shares of the prerevenue biotech Geron Corporation ( GERN -3.62% ) gained an astounding 41% during the first six months of 2019, according to data from S&P Global Market Intelligence. What caused investors to pile into this clinical-stage biotech stock in the first half of the year?

Geron's stock has been marching higher in response to the news that its telomerase inhibitor, imetelstat, will enter a pivotal-stage trial for the rare blood disorder known as lower-risk myelodysplastic syndromes (MDS) this summer.

An open road with the word "recovery" painted across it in bold letters.

Image Source: Getty Images.

So what

While imetelstat is still a few years away from a possible regulatory approval, the drug could end up generating hundreds in millions in sales if approved for MDS. That's a healthy commercial opportunity for a company with a market cap of only $261 million at the time of writing.

Unfortunately, imetelstat might have to battle Celgene and Acceleron Pharma's luspatercept for a piece of the MDS pie. The two biotechs, after all, recently announced that the U.S. Food and Drug Administration (FDA) has officially accepted luspatercept's biologics license application for review. The FDA will reportedly make a final decision on the drug's MDS indication by April 4, 2020.

Now what

Assuming everything goes according to plan, Geron's rival MDS drug could be on the market by late 2022 or perhaps early 2023. That's the good news. The bad news is that Geron will almost certainly have to raise capital well before this seminal event takes place.

Point blank, the biotech's remaining $170 million in cash and marketable securities simply won't cover the full cost of imetelstat's late-stage development. Therefore, investors shouldn't buy this speculative biotech stock without accepting the fact that Geron will probably have to dilute current shareholders at some point within the next two years. That's not the end of the world, but a sizable capital raise may cool off the biotech's upward momentum.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Geron Corporation Stock Quote
Geron Corporation
GERN
$1.33 (-3.62%) $0.05
Celgene Corporation Stock Quote
Celgene Corporation
CELG
Acceleron Pharma Stock Quote
Acceleron Pharma
XLRN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.